Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mediwound Ltd Ord Sh (NQ: MDWD )

17.99 +0.34 (+1.93%)
Streaming Delayed Price Updated: 10:11 AM EDT, May 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Mediwound Ltd Ord Sh

< Previous 1 2 Next >
MediWound to Present Phase 2 EscharEx® Data at the Symposium on Advanced Wound Care (SAWC) Spring 2023
From MediWound Ltd.
Via GlobeNewswire
MediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company Update
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer
From MediWound Ltd.
Via GlobeNewswire
MediWound Expands its Global Leadership Team to Help Drive Company’s Future Growth
From MediWound Ltd.
Via GlobeNewswire
MediWound to Report Fourth Quarter and Year-End 2022 Financial Results
Conference Call and Webcast Scheduled for Thursday, March 16 at 8:30 am Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
MediWound to Present Corporate Highlights at Upcoming Investor Conferences
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Closing of $27.5 Million Registered Direct Offering of Ordinary Shares
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares Priced At-The-Market
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
From MediWound Ltd.
Via GlobeNewswire
MediWound Expands NexoBrid’s Global Presence with Marketing Approval in Japan
From MediWound Ltd.
Via GlobeNewswire
MediWound Strengthens European Presence of NexoBrid®
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
From MediWound Ltd.
Via GlobeNewswire
MediWound Expands Global Presence as NexoBrid® Gains Approval in India
Exclusive marketing and distribution agreement signed with Bharat Serum and Vaccines Limited (BSV), a leading biopharmaceutical company 
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces a 1-for-7 Reverse Share Split
From MediWound Ltd.
Via GlobeNewswire
MediWound to Report Third Quarter 2022 Financial Results
Conference Call and Webcast Scheduled for Tuesday, November 15, 2022 at 8:30 am Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Formation of Strategic Advisory Board
Esteemed group of industry leaders to contribute expertise and experience to MediWound’s strategic and operational activities 
From MediWound Ltd.
Via GlobeNewswire
MediWound's EscharEx® Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022
EscharEx’s promising results from the completed Phase 2 trials were highlighted 
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Closing of the Concurrent Registered Direct and Private Placement Offerings
Gross Proceeds of $30.5 Million Raised 
From MediWound Ltd.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.